Abstract
New challenges and the state of development of COVID-19 in connection with the spread of new strains of SARS-CoV-2 have been analyzed. Experience and knowledge in working with new means of protection of different types of vaccines are studied: both classic, based on inactivated virus or its fragment, and the new generation – with vector and genetic mRNA vaccines, as well as effective antiviral drugs. Biorisks and compliance with biosafety principles have been studied. The replenishment of the base of competencies for biotechnologists and pharmacists in the context of distance learning and response to the pandemic is considered. The new data were used to introduce and deepen knowledge about the new generation of vaccines and the dangers of dual use of experimental data in the development of new components of educational programs in "Biotechnology and Bioengineering" and “Pharmacy, Industrial Pharmacy”.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
